The Package-Deal Fallacy in Government Regulation of Pharmaceuticals by Harrison Borough

Medicines in Australia are regulated under the Therapeutic Goods Act 1989. Before a medicine can be imported, manufactured, or sold, it must be approved by the Therapeutic Goods Administration (TGA) and registered on the Australian Register of Therapeutic Goods (ARTG).

This framework is presented as necessary for “pharmaceutical safety.” In practice, however, it grants the government a legal monopoly over which medicines Australians may access. Every pharmaceutical substance, regardless of its nature or level of risk, must first pass through the same central regulatory system.

The justification for this system rests on a conceptual confusion: the package-deal fallacy.

In The Metaphysical Versus the Man-Made, Ayn Rand defined a package-deal as the error of treating fundamentally different things as though they belong in the same conceptual category. The concept of “regulation” frequently functions in precisely this way. The same word is used to describe both laws that protect individual rights and laws that violate them. Once these radically different categories are bundled together under a single term, opposition to coercive government control can be dismissed as opposition to safety itself.

But laws against fraud and laws prohibiting voluntary exchange are not the same thing.

Rights-Respecting vs Rights-Violating Laws

Rights-respecting pharmaceutical laws prohibit deception, contamination, false advertising, and negligence. A pharmaceutical company that lies about its product, conceals side effects, or sells contaminated substances should be held legally liable. Such laws protect property rights, bodily autonomy, and voluntary exchange.

Rights-violating laws are fundamentally different. These laws prohibit producers from manufacturing or selling substances unless they first receive government approval. They prohibit doctors from prescribing substances the state has not authorised. They prohibit patients from purchasing substances bureaucrats have decided they should not access.

This distinction is often obscured because both categories are grouped together under the single heading of “regulation.” A person who objects to the TGA deciding which substances may legally exist on the market is then treated as though he objects to laws against contamination or fraud.

But preventing fraud does not require prohibiting peaceful exchange.

Treatment Obstruction by Regulatory Monopoly

The treatment of ibogaine in Australia demonstrates this clearly.

Ibogaine is classified as a Schedule 4 substance by the TGA and is not listed on the ARTG. In practice, broader state and federal law render it effectively prohibited outside tightly controlled research contexts. Access requires approval from both the TGA and a Human Research Ethics Committee, making it practically inaccessible for ordinary patients.

Yet ibogaine has demonstrated potential therapeutic applications in the treatment of substance-use disorders and post-traumatic stress disorder. Australians seeking access often travel overseas because they cannot legally obtain treatment domestically.

This is not an isolated phenomenon. Regulatory agencies have repeatedly delayed or obstructed access to therapeutics later regarded as medically valuable.

During the AIDS crisis of the 1980s, activists fiercely criticised the United States Food and Drug Administration (FDA) for the extraordinary length of drug approval timelines while thousands of patients were dying. Experimental drugs that terminally ill patients desperately wanted access to remained tied up in clinical and bureaucratic processes. Public pressure eventually forced the FDA to accelerate approval pathways, but not before the lives of patients willing to accept the risks of taking a promising but government-unapproved drug were needlessly lost.

The Incentives of a Free Market

Critics often speak as though pharmaceutical safety would disappear in the absence of state control. In reality, strong incentives for safety already emerge naturally wherever producers must compete for consumer trust.

Pharmaceutical companies would still possess powerful incentives to produce safe and effective therapeutics. Unsafe products would expose firms to lawsuits, reputational destruction, collapsing investor confidence, and catastrophic financial losses. Companies that consistently produced effective medications would gain market trust and profit from it.

This incentive structure already exists throughout countless industries involving health and safety.

Consider the whiskey industry. How many bottles from a major whiskey producer would need to be discovered containing methanol before consumers stopped buying the product, retailers removed it from shelves, investors fled, and lawsuits threatened the company’s survival? Very few.

Importantly, methanol poisoning was vastly more common during alcohol prohibition, when alcohol production was driven underground into black markets lacking accountability, transparency, and quality control. When legal production disappears, safety mechanisms do not become stronger. They become weaker.

The same principle applies elsewhere. In 1982, the Johnson & Johnson Tylenol cyanide murders led to a massive nationwide product recall despite the contamination occurring externally rather than during manufacturing. The company absorbed enormous financial losses because preserving public trust was more important to the company than short-term profit. The incident also accelerated the widespread adoption of tamper-proof packaging standards across the pharmaceutical industry.

Likewise, automotive manufacturers spend enormous sums on safety engineering because catastrophic failures destroy consumer trust and trigger massive liability exposure. A company whose brakes repeatedly fail does not survive by insisting consumers “trust the process.” Airlines cannot repeatedly have aircrafts crash while retaining public confidence. 

Pharmaceuticals would be no different.

A company that produced contaminated, ineffective, or dangerous therapeutics would rapidly acquire a reputation for unreliability and lose its market position. Hospitals, pharmacies, insurers, physicians, third-party evaluators, and patients would avoid its products. By contrast, firms with strong records of safety and efficacy would acquire enormous competitive advantages. In a free market, trust becomes an undeniable economic asset.

Independent Evaluators and Competitive Standards

A free pharmaceutical market would not imply the absence of standards. It would imply that standards emerge competitively rather than through government monopoly.

Independent third-party evaluators would likely arise to test pharmaceuticals, certify safety standards, publish efficacy data, and endorse products meeting their requirements. These organisations would compete on both the rigour of their evaluations and the credibility of their recommendations.

A comparable process already exists in the automotive industry. Consumer demand for safer vehicles helped drive the rise of independent crash-testing organisations and incentivised manufacturers to improve safety standards voluntarily.

The same dynamic exists throughout modern markets. Consumers rely on Underwriters Laboratories for electronics certification, accounting firms for auditing, credit-rating agencies for financial assessments, and independent testing organisations such as Consumer Reports for product reliability. Hospitals and physicians already rely heavily on independent journals, clinical studies, insurance standards, and professional associations rather than government approval alone.

In a free market, healthcare providers could prescribe therapeutics based on evidence, patient outcomes, independent certification, and professional judgement. Consumers could choose products backed by evaluators whose standards they trust.

The likely result would include faster therapeutic innovation, lower costs through competition, greater treatment diversity, and the emergence of specialised safety-certification industries competing for credibility and public trust.

The Black Market Problem

Critics of pharmaceutical freedom often argue that legalisation would increase access to dangerous substances such as methamphetamine or cocaine.

But these substances already exist. The question is not whether dangerous drugs will exist, but under what conditions they will exist.

Black markets systematically eliminate many of the incentives that improve safety in legal markets. Illegal producers cannot openly build reputations, rely on formal contracts, advertise accurate quality standards, or submit to public scrutiny. Consumers cannot reliably verify purity or dosage.

Fentanyl provides a striking example. This synthetic opioid, many times more potent than morphine, is frequently mixed into illicit street drugs such as cocaine and methamphetamine without users’ knowledge, significantly contributing to overdose deaths.

Alcohol prohibition produced similar effects. Illegal alcohol production during Prohibition was frequently contaminated or improperly distilled, contributing to poisonings and blindness. Organised crime flourished precisely because legal production had been abolished.

A legal market would not eliminate dangerous substances, but it would radically alter the incentives surrounding them. Producers would possess incentives toward accurate dosing, reliable purity standards, transparent labeling, and product consistency. Third-party testing and certification services could emerge for recreational substances just as they could for therapeutic ones.

Nor does legality compel consumption. Pharmacies would remain free to refuse to stock particular substances or require prescriptions for high-risk medications.

Conclusion

The regulation of pharmaceuticals in Australia - and everywhere else - relies on packaging two fundamentally different phenomena under the single concept “regulation”: the legitimate prevention of fraud, and the coercive restriction of voluntary exchange.

A rights-respecting legal framework would punish deception, contamination, negligence, and false advertising while leaving peaceful individuals free to produce, prescribe, purchase, and consume substances voluntarily.

The current system instead grants the state coercive authority over which therapeutics may legally exist at all.

The result is slower innovation, restricted treatment access, higher barriers to experimentation, and the replacement of individual judgement with bureaucratic permission in one of the most important domains of human life: control over one’s own body.